SML3961

Paricalcitol

≥98% (HPLC)

• Synonym(s): (1R,3R)-5-((E)-2-((1R,3aS,7aR)-1-((2R,5S,E)-6-hydroxy-5,6-dimethylhept-3-en-2-yl)-7a-methyldihydro-1H-inden-4(2H,5H,6H,7H,7aH)-ylidene)ethylidene)cyclohexane-1,3-diol, (1alpha.3beta,7E,22E)-19-Nor-9,10-secoergosta-5,7,22-triene-1,3,25-triol, (7E,22E)-19-Nor-9,10-secoergosta-5,7,22-triene-1alpha,3beta,25-triol, 19-Nor-1alpha,25-dihydroxyvitamin D2
• Empirical Formula (Hill Notation): C₂₇H₄₄O₃
• CAS Number: 131918-61-1
• Molecular Weight: 416.64
• UNSPSC Code: 12352200
• NACRES: NA.77

Properties

• Quality Level: 100
• Assay: ≥98% (HPLC)
• form: powder
• color: white to beige
• solubility: DMSO: 2 mg/mL, clear
• storage temp.: -10 to -25°C

Description

Biochem/physiol Actions

Agonist for the calcitriol (Vitamin D receptor); Vitamin D analog; Antihyperparathyroid.

Paricalcitol is Vitamin D analog that acts as an agonist for the calcitriol receptor (Vitamin D receptor, VDR). It suppresses parathyroid hormone (PTH) gene transcription and PTH secretion and has been used clinically because of its antihyperparathyroid activity without inducing hypercalcemia or hyperphosphatemia. There is growing evidence that vitamin D either directly or indirectly affects cardiac structure and function. Paricalcitol showed improvement of cardiac function after myocardial infarction in mice with decreases in biomarkers, apoptosis, inflammation, and fibrosis.

Safety Information

• Pictograms: GHS06,GHS08
• Signal Word: Danger
• Hazard Statements: H301 + H311,H330,H372
• Precautionary Statements: P260 - P264 - P280 - P302 + P352 + P312 - P304 + P340 + P310 - P314
• Hazard Classifications: Acute Tox. 2 Inhalation - Acute Tox. 3 Dermal - Acute Tox. 3 Oral - STOT RE 1 Oral
• Storage Class Code: 6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials
• WGK: WGK 3
• Flash Point(F): Not applicable
• Flash Point(C): Not applicable